Isolation and characterization of tumorigenic, stem-like neural precursors from human glioblastoma by R. Galli et al.
[CANCER RESEARCH 64, 7011–7021, October 1, 2004]
Isolation and Characterization of Tumorigenic, Stem-like Neural Precursors from
Human Glioblastoma
Rossella Galli,1 Elena Binda,1 Ugo Orfanelli,1 Barbara Cipelletti,1 Angela Gritti,1 Simona De Vitis,2 Roberta Fiocco,1
Chiara Foroni,1 Francesco Dimeco,3,4 and Angelo Vescovi1,5
1Stem Cell Research Institute and 2Laboratory of Molecular Diagnostics, H. S. Raffaele, Milan, Italy; 3National Neurological Institute “C. Besta,” Milan, Italy; 4Department of
Neurological Surgery, Johns Hopkins Medical School, Baltimore, Maryland; and 5Department of Biological Sciences and Biotechnology, University of Milano-Bicocca, Milan,
Italy
ABSTRACT
Transformed stem cells have been isolated from some human cancers.
We report that, unlike other brain cancers, the lethal glioblastoma mul-
tiforme contains neural precursors endowed with all of the critical fea-
tures expected from neural stem cells. Similar, yet not identical, to their
normal neural stem cell counterpart, these precursors emerge as unipo-
tent (astroglial) in vivo and multipotent (neuronal-astroglial-oligodendro-
glial) in culture. More importantly, these cells can act as tumor-founding
cells down to the clonal level and can establish tumors that closely resem-
ble the main histologic, cytologic, and architectural features of the human
disease, even when challenged through serial transplantation. Thus, cells
possessing all of the characteristics expected from tumor neural stem cells
seem to be involved in the growth and recurrence of adult human glio-
blastomas multiforme.
INTRODUCTION
Cancer arises from a series of mutations occurring in few or single
founder cells. From a therapeutic standpoint, a critical issue regards
the elucidation of the identity and physiology of the cell(s) responsible
for tumor formation, progression, and recurrence (1). With some
exceptions (2), the identity of tumorigenic cells within many cancers
remains unclear, but recent observations point to the involvement of
somatic stem cells in oncogenesis (3). Embryonic and fetal stem cells
may accumulate mutations during their expansion/growth phase
throughout development and may form full-blown tumors in adult-
hood (3), whereas adult stem cells and their progeny may represent the
direct target of oncogenic transformation in mature tissues (1). Ac-
cordingly, the involvement of cells displaying a stem cell phenotype
in cancer formation and progression (1) has been confirmed in acute
myeloid leukemia (4–6) and breast cancer (2).
If stem cells and/or their progeny represent the main target of
neoplastic transformation, it is then reasonable to infer that the main
foci of malignant transformation ought to coincide with those tissue
regions that embody somatic stem cells. Indeed, the main areas of
distribution of certain brain tumors overlap specific regions of the
central nervous system (CNS; refs. 7 and 8) that comprise glia-like
neural stem cells and their progeny (9, 10). Accordingly, deregulation
of specific proto-oncogenes such as Ink4A/Arf, epidermal growth
factor (EGF) receptor, and c-myc (11–13) or expression of SV40 T
antigen (14) in glial fibrillary acidic protein (GFAP)- or nestin-
expressing neural cells induces high-grade gliomas in brain areas that
contain neural stem cells.
Recently, transformed, stem-like neural progenitors have been iso-
lated and cultured from human brain tumor tissues (15–17), which
raises fundamental issues concerning their actual ability to drive
cancer growth and recurrence (18).
Here, we report the initial finding that glioblastoma multiforme, the
most malignant among the adult human CNS tumors, comprises
transformed precursors that bear the full complement of functional
characteristics expected from stem cells (19), including the capacity
for tumor generation. In fact, these cells can establish tumors with all
of the classical features of human glioblastomas multiforme, even
upon serial transplantation and, therefore, can be identified as tumor
neural stem cells (20).
MATERIALS AND METHODS
Sample Classification. All of the samples were classified according to
World Health Organization guidelines. Lines 0627, 0821, 0913, 1022, and
1205 were obtained from patients with diagnosis of primary glioblastoma; line
1030 was derived from a patient suffering from secondary glioblastoma.
Patients from whom lines 0627, 0821, 0913, and 1022 were established
underwent recurrence after 6 to 12 months post-surgery.
Primary Culture, Culture Propagation, Population Analysis, and Clon-
ing. Tumor samples, either derived from patients or from orthotopic trans-
plantation of glioblastoma multiforme–derived cell lines, were processed as by
Gritti et al. (21). Primary cells were plated in 25 cm2 tissue culture flasks
plated at clonal density (2500–5000 cells/cm2) in Dulbecco’s modified Eagle’s
medium/F-12 medium containing 20 ng/mL of both EGF and fibroblast growth
factor (FGF2; Peprotech, Rocky Hill, NY). As reference cell lines, normal
human fetal neural stem cells (22) and the glioblastoma cell line U87MG were
used in all of the assays. Population and serial subclonogenic analysis were
performed as by Galli et al. (23).
Differentiation of Stem Cell Progeny and Immunocytochemistry. To
assess for multipotency, cells were plated at a density of 2.5  104 cells/cm2
onto Matrigel-coated glass coverslips (12 mm diameter) in the presence of
leukemia inhibitory factor (10 ng/mL; ref. 24) for 7 to 10 days. Multiple
immunofluorescence assays for neural antigens were performed as described
by Gritti et al. (21) and Galli et al. (23).
Evaluation of Tumorigenicity by Subcutaneous Injection and by Or-
thotopic Injection. Tumorigenicity was determined by injecting glioblastoma
multiforme–derived neural stem cells, U87, and human fetal neural stem cells,
either subcutaneously (s.c.) or orthotopically. Cells (3  106) in 100 L of PBS
were s.c. injected into the right flank of Scid/bg mice while 2 L of a 1  108
cells/mL cell suspension in PBS were delivered into the right striatum (0.2
L/min) by stereotactic injection through a glass electrode connected to a Ham-
ilton syringe. The following coordinates were used: antero-posterior  0; medio-
lateral  2.5 mm; dorso-ventral  3.5 mm. Mice were sacrificed at different
times between 1 and 10 weeks post-injection, according to the cell line originally
injected. Hematoxylin and eosin staining and immunohistochemistry were per-
formed on 15-m-thick cryostat sections. Sections were processed as by Vescovi
et al. (22). Antibodies/antisera used were as follows: mouse antivimentin (1:200;
Chemicon, Temecula, CA), mouse antihuman mitochondria (1:20; Chemicon),
mouse antihuman nuclei (1:20; Chemicon), mouse anti-Galactocerebroside C (Gal
C; 1:20; Chemicon), mouse antineuronal class III -tubulin (Tuj1; 1:500; Babco,
Richmond, CA), rabbit anti-GFAP (1:1000; Dako Corporation, Carpinteria, CA),
rabbit antilaminin (1:200; Sigma, St. Louis, MO), and rabbit anti-Ki67 (1:1000;
NovoCastra, Newcastle, UK).
Chromosome Analysis. Cells were treated with medium containing 10
g/mL Colcemid (Irvine Scientific, Santa Ana, CA) for 1 to 2 hours and
resuspended in hypotonic 1% sodium citrate at room temperature for 30
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minutes. The cells were then washed in methanol-acetic acid (3:1, v/v) fixative
solution for 30 minutes and spread onto clean dry slides. Q-banding staining
was then performed, and 10 metaphases were analyzed for each sample.
Telomeric Repeat Amplification Protocol and Telomere Length Assess-
ment. Telomerase activity was detected using the PCR-based TRAPeze Te-
lomerase Detection kit (Intergen, Purchase, NY), according to the manufac-
turer’s instructions. Total proteins (150 ng) were loaded into each lane. For the
telomere length assay, the length of the telomeres was determined using
TeloTAGGG Telomere Length Assay (Roche, Gipf-Oberfrick, Switzerland)
according to the manufacturer’s instructions. Two g of genomic DNA of each
sample were digested with a HinfI/RsaI mixture for 2 hours at 37°C and then
loaded into a 0.8% agarose gel.
Molecular Analysis. One g of total RNA from tumor neural stem cells,
U87, and human fetal neural stem cells, extracted using the RNeasy Mini kit
(Qiagen, Chatsworth, CA), was primed with oligo(dT) for cDNA synthesis and
reverse-transcribed by using Superscript RNase H Reverse Transcriptase
(Life Technologies, Rockville, MD). All cDNAs used as templates were
previously normalized throughout a -Actin reverse transcriptase-PCR. Se-
quence of primers and PCR conditions are available on request.
RESULTS
Selection and Expansion of Neural Precursors from Adult Hu-
man Brain Tumors. To assess for the presence of neural precursors
within human brain tumors, cells from post-surgery specimens of
low-grade gliomas, glioblastoma multiformes, or high-grade medul-
loblastomas were plated at clonal density (21) in serum-free medium,
containing EGF and FGF2. This provides a stringent, low-density
system (5  103 cells/cm2), which selects away differentiated/
differentiating cells in primary CNS cultures, leaving neural stem cells
free to proliferate and expand exponentially (25, 26).
Twenty to 40 days after plating, phase-bright clones resembling the
classical neurospheres formed in vitro by normal neural stem cells
(ref. 27; Fig. 1A and B) were detected in all of the cultures established
from high-grade glioblastoma multiformes and medulloblastomas.
Clonal frequency was between 0.5 and 31% of the total cells plated for
glioblastomas multiforme (n  12) and 50 and 80% for medulloblas-
tomas (n  4). Conversely, clone formation was never observed in
cultures from either World Health Organization grade I gliomas or
World Health Organization grade II oligodendrogliomas (n 5; up to
90 days in vitro). These data confirm and extend previous findings
(15–17), which show that EGF/FGF2-responsive precursors are spe-
cifically found in glioblastomas multiforme and medulloblastomas.
Glioblastomas Multiforme Contain Multipotent Precursors En-
dowed with Long-term Self-renewal. The generation of clones from
disaggregated primary cancers provides an index of the cancer clo-
nogenicity (20). However, the sole formation of neurospheres in
cultured CNS tumors does not provide, per se, the demonstration of
Fig. 1. Analysis of long-term proliferation in glioblastoma multiforme–derived tumor neural stem cells. Phase-bright microphotographs showing examples of glioblastoma
multiforme–derived (A) and medulloblastoma-derived (B) neurospheres; 20 objective. C. Intrinsic differences in the growth rate were observed among cluster A, consisting of
faster-growing tumor neural stem cells such as 0627, 0913, and 1022 (black lines), and cluster B, comprising slower-expanding glioblastoma multiforme (GBM) cell lines 0821, 1030,
and 1205 (red lines). Although medulloblastoma (MDB) tissues displayed the highest content of clonogenic cells (up to 80%), they never established tumor neural stem cells lines (green
lines). D. Differently from normal human fetal neural stem cells (22), glioblastoma multiforme–derived tumor neural stem cells displayed different rates of amplification at low- and
high-subculturing stages, as shown for cell line 0627. E. The exposure of cell line 0627 to EGF or FGF2 influenced the proliferation rate, which was higher in the presence of both
mitogens and lower when using only one factor, as shown previously for normal human fetal neural stem cells (22).
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the presence of tumor neural stem cells therein. Transiently amplify-
ing precursors are also known to produce neurospheres in this system,
and they can even undergo a limited number of passages in culture
(20, 28). In addition, neurosphere formation may also result from
spontaneous cell aggregation, usually as the consequence of excessive
plating density (29).
Hence, we determined whether the clonogenic cells in our primary
glioblastoma multiforme and medulloblastoma cultures represented
transient clonogens as generated by short-term proliferating, transit
amplifying cells or possessed the cardinal properties expected from
cultured tumor neural stem cells (20). To this end, we assessed their
capacity for long-term proliferation, self-renewal, multipotency (the
ability to generate the three major neural cell types, i.e., neurons,
astroglia, and oligodendroglia) and their tumorigenicity (27, 30–32),
by combining cloning, subcloning, and population analysis followed
by orthotopic, heterotopic, and serial transplantation assays.
One of the primary consequences of dealing with candidate stem
cells endowed with extensive self-renewal capacity is the establish-
ment of steadily expanding, stable lines (19, 28). Surprisingly, al-
though medulloblastoma cultures displayed the highest clonogenic
capacity, they failed in establishing long-term cell lines (four of four
specimens) under the conditions normally used for neural stem cells
expansion. In agreement with previous findings (16, 17), medullo-
blastoma cultures could be propagated for a few passages (Fig. 1C),
although in our hands, they could only generate Tuj1-immunoreactive
cells when triggered to differentiate (data not shown). Conversely,
under identical culture conditions, one-half of the 12 cultures estab-
lished from glioblastomas multiforme comprised multipotent precur-
sors, which established long-term expanding cultures. These six dif-
ferent glioblastoma multiforme–derived lines were expanded for
more than 80 passages, with an average doubling time of 3 to 4 days
(i.e., 180–280 days in vitro), and were characterized as tumor neural
stem cells through the comparison with normal human fetal neural
stem cells (22) and with the well-characterized human glioblastoma
cell line U87MG.
Human glioblastoma multiforme cell lines were named after the
date of surgery: 0627, 0821, 0913, 1022, 1030, and 1205. When their
growth rate was assessed, significant differences between specific
lines emerged (Fig. 1C). Nonetheless, despite the fact that the kinetics
of expansion was characteristic for each tumor cell line and clearly
depended upon the specimen of origin, all of the lines exponentially
expanded in number, similarly to normal human fetal neural stem cells
and U87 cells and as opposed to their medulloblastoma counterpart
(Fig. 1C). Based on growth properties, two distinct clusters emerged:
cluster A, comprising faster-growing lines 0627, 0913, and 1022; and
cluster B, consisting of slower-expanding lines 0821, 1030, and 1205
(Fig. 1C). Of note, whereas normal human fetal neural stem cells
displayed steady growth capacity over long-term culturing (22, 33),
the proliferative activity of glioblastoma multiforme–derived cell
lines increased at very late subculturing stages (120–150 days in
vitro) compared with earlier passages (15–35 days in vitro; Fig. 1D, in
reference to line 0627). This may reflect their progressive enrichment
in cells endowed with aberrant proliferative advantage, the tumor cell
adaptation to the culture conditions, or the intrinsic, genetic fluctua-
tion expected from tumor cells. Nonetheless, this phenomenon was
the only hint as to a possible, latent instability of glioblastoma
multiforme–derived cell lines, which displayed an otherwise remark-
ably stable cellular and molecular phenotype and karyotype (see next
sections).
Additional proof that tumor neural stem cells were the likely
founders of glioblastoma multiforme–derived cell lines came from the
observation that single glioblastoma multiforme cells could give rise
to clonal cell lines, which behaved identically to their parental (i.e.,
bulk culture) cell lines (not shown). These clonal tumor neural stem
cells were used in all of the experiments described from now on.
We continued by analyzing the response of our candidate tumor
neural stem cells to mitogens that regulate proliferation in normal
neural stem cells (22, 34, 35). As described for adult rodent neural
stem cells (34), glioblastoma multiforme–derived cell lines expanded
slowly in the presence of the sole FGF2, switched to a faster growth
mode when exposed to EGF alone, and expanded even faster when
exposed to both mitogens simultaneously (Fig. 1E, cell line 0627).
Thus, glioblastoma multiforme cells respond to the same mitogenic
cues that control the fate of normal neural stem cells.
We then assessed tumor neural stem cell multipotency by deter-
mining the ability of clonal glioblastoma multiforme–derived cells to
generate neurons, astrocytes, and oligodendrocytes. Early passage
(passages 10–15) clonally derived glioblastoma multiforme cells un-
derwent terminal differentiation upon removal of mitogens (34, 36)
and the subsequent addition of leukemia inhibitory factor to the
medium, as shown previously for human fetal neural stem cells (24).
Similar to normal neural stem cells (34), all of the glioblastoma
multiforme clonal lines differentiated into GFAP-positive astrocyte-
like cells (Fig. 2B and F) but also into neuron-like cells, which were
immunoreactive for Tuj1 (Fig. 2A and E), MAP5 (Fig. 2I), MAP2
(Fig. 2J), neurofilament Mr 200,000 (NF200; Fig. 2K), glutamate (Fig.
2L), and -aminobutyric acid (Fig. 2M) and into GalC-immunoreac-
tive oligodendrocyte-like cells (Fig. 2D and H). Conversely, U87 cells
never gave rise to cells immunoreactive for any of the above pan-
neural antigens, thus demonstrating that multipotency is a unique
property of glioblastoma multiforme–derived cells. Such multipo-
tency was maintained unaltered even after extensive culturing, up to
passage 80 (not shown). Notably, glioblastoma multiforme–derived,
differentiated cultures comprised a fraction of cells, which colabeled,
promiscuously, with neuronal and glial markers (Fig. 2C and G). This
abnormal type of cells was never observed in normal human fetal
neural stem cells and likely reflects the activation of an aberrant
differentiation program in tumor neural stem cells, as expected from
developmentally deregulated tumor cells. Intriguingly, this same frac-
tion of promiscuously double-labeled cells varied between each cell
line and correlated with the proliferation capacity index, with cluster
A glioblastoma multiforme cells (fast-growing), showing the highest
content of abnormal end cells, and cluster B lines (slow-growing),
displaying a smaller proportion and a behavior somewhat reminiscent
of normal human fetal neural stem cells (Fig. 2, table).
Ultimately, the self-renewal capacity of glioblastoma multiforme
cells was assessed directly, using subcloning experiments by which
the number of stem cells in a given clonal neurosphere can be
determined by assessing the number of secondary neurospheres gen-
erated after dissociation of the clone itself (23, 28, 34). This measure
also provides both an estimate of the relative frequencies between
symmetric proliferative divisions and symmetric differentiative divi-
sions and an indirect index of the capacity of the stem cell population
for size expansion (23, 28, 37). The generation of multiple secondary
clones could be observed in all of the lines tested (line 0627,
68.0  5.0; line 0913, 55.3  4.0; line 1022, 85.0  5.0; line 0821,
28.0  8.0; line 1030, 26.1  2.2; line 1205, 63.8  4.0; human fetal
neural stem cells, 37.9 6.0; U87, 90.0 5.0; means SEM, n 4,
Student’s t test,  P 0.001). When the six different cell lines were
compared with each other, a significantly lower frequency of prolif-
erative symmetric divisions was detected in some of the slow-growing
cell lines (0821 and 1030) compared with the other lines. This is
indicative of an inherent difference in the self-renewal capacity be-
tween the different glioblastoma multiforme–derived tumor neural
stem cell lines, which strictly correlates with their clonogenic ability
and their growth profile.
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These findings show that glioblastoma multiformes contain multi-
potent, long-term self-renewing, population-expanding cells that sat-
isfy all of the defining criteria expected from tumor neural stem cells
in vitro. Nonetheless, because the most critical attribute of tumor stem
cells is their capacity to generate and perpetuate their tumor of origin
(20), we sought to verify whether our glioblastoma multiforme–
derived tumor neural stem cells could function as tumor-founding
cells by assessing their actual ability to give rise to tumors in vivo.
The In vivo Tumorigenic Potential of Tumor Neural Stem Cells.
When injected into immunosuppressed animals, both s.c. and intracra-
nially (i.c.), all of the six tumor neural stem cell lines reproducibly
established tumors, with a take efficiency of 50% s.c and 100%
orthotopically, whereas normal human fetal neural stem cells always
failed. When compared with classical U87-derived tumors, tumor
neural stem cell–derived gliomas developed at a much slower rate.
The first appearance of well-defined tumor masses could be observed
after 1 week s.c. and 3 weeks i.c. in U87-treated animals, whereas it
took at least 6 weeks s.c. and 7 weeks i.c. to observe the same extent
of tumorigenesis in glioblastoma multiforme–derived, tumor neural
stem cell–transplanted animals.
Histopathologic analysis of s.c. generated tumor neural stem cell–
derived tumors demonstrated an unprecedented, striking glioblasto-
ma-like tissue pattern. This was characterized by the presence of (1)
several areas of necrosis surrounded by typical pseudo-palisade struc-
tures (Fig. 3A), (2) elevated vascular proliferation as demonstrated by
laminin staining (Fig. 3B), (3) GFAP immunoreactivity (Fig. 3C), and
(4) many mitotic figures, as measured by Ki67 (not shown), which
were significantly higher than U87-derived tumors (3.68  0.58% for
line 0627-derived tumor versus 1.38 0.13% for U87-derived tumor;
n  4, P  0.01, Student’s t test). Notably, tumors derived from U87
implantation never displayed any glioblastoma-specific feature.
Rather, they were characterized by the presence of cells with globoid
Fig. 2. Differentiation potential of fast- and slow-expanding tumor neural stem cells. Analysis of the multipotency of the fast-growing line 0627 (representative of cluster A, passage
13; A–D) and slow-growing line 0821, (representative of cluster B, passage 15; E–H) by immunofluorescence for neuronal (Tuj1; red in A, C, E, and G), glial (GFAP; green in B, C,
F, and G) and oligodendroglial (GalC; red in D and H) markers. Additional markers of neuronal differentiation were also detected [line 0821, MAP5, MAP2, and NF200, red in I, J,
and K; glutamate and -aminobutyric acid (GABA), green in L and M]. Cells that colabeled promiscuously with both neuronal and glial markers (arrows in C and G) could be observed
in all of the cell lines established; magnification, 20. The table shows a quantitative analysis of the differentiation capacity of the various glioblastoma multiforme–derived tumor
neural stem cell lines, normal human fetal neural stem cells, and U87 cells with respect to their ability to generate cells of the three major neural lineages and to cells that display aberrant,
promiscuous neuronal/astroglial colabeling.
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cytoplasm, which lacked fibrillary structures and hyperchromatic nu-
clei, the typical hallmarks of highly malignant gliomas (Fig. 3D).
Strikingly, when transplanted orthotopically, tumor neural stem
cells were able to form i.c. tumors, which displayed an elevated extent
of proliferation and an exacerbated migratory and infiltration capa-
bility, distinctive of human glioblastomas multiforme. As shown by
hematoxylin and eosin staining, tumor neural stem cells generated
highly anaplastic tumors, characterized by marked nuclear atypia and
high mitotic index (hematoxylin and eosin in Fig. 3E). Conversely,
unlike any typical glioblastoma, U87 cells gave rise to enormous but
well-delimitated tumor masses, which developed strictly within the
area of injection (hematoxylin and eosin in Fig. 3F). On the same line,
the i.c. tumors derived from tumor neural stem cells displayed a very
peculiar histomorphology. Six weeks after implantation, peculiar nest-
like structures, composed of highly mitotic polymorphic cell nuclei,
identified as aberrant glial elements, could be retrieved especially in
the center of the lesion (Fig. 3E, inset). Due to the physical constraints
imposed by the walls of the skull, the maximum level of growth
reached by i.c. tumor neural stem cell–derived tumors did not allow
the formation of clear areas of necrosis (pseudo-palisades), as opposed
to s.c. tumors, which were allowed to grow up to 5 cm3. In agreement
with findings on s.c. tumors, also orthotopic U87-derived lesions did
not show any cyto-architectural similarity with the actual human
disease (Fig. 3F, inset).
Most importantly, by staining with human-specific antimitochon-
dria, tumor neural stem cell–derived tumor cells were shown to
escape the site of transplantation, infiltrating both the adjacent paren-
chyma and the corpus callosum, even extending into the contralateral
hemisphere, as bipolar migrating cells (Fig. 4A). Consistent with our
in vitro findings and with the study of Hemmati et al. (17), when
passage seventh medulloblastoma-derived cells were transplanted or-
thotopically, after 6 weeks from transplantation, no sign of tumor
formation could be observed, and the transplanted cells did not mi-
grate significantly from the graft (Fig. 4B). The same noninfiltrative
behavior could be observed in U87-derived tumors (Fig. 4C).
Notably, when i.c. tumors generated by glioblastoma multiforme–
derived tumor neural stem cells were characterized for the expression
of specific antigens, they displayed an intense mitotic activity as
shown by Ki67 staining (Fig. 4D, double-labeled cells in yellow),
whereas the graft established by medulloblastoma cells contained
fewer proliferating cells (Fig. 4E). Moreover, the tumors established
by glioblastoma multiforme–derived tumor neural stem cells were
Fig. 3. Histopathologic features of tumor neural
stem cell–derived s.c. and i.c. tumors. A. Large
areas of necrosis surrounded by highly packed tu-
mor cells (“pseudopalisade”) were identified within
the tumors generated by s.c. transplantation of tu-
mor neural stem cells into scid/bg mice. Extensive
neovascularization of the tumor tissue by laminin
staining (B; 10 objective) as well as widespread
and intense GFAP immunoreactivity (C; 20 ob-
jective) could be retrieved. D. U87-derived tumors
did not display any of the peculiar histomorpho-
logic features, typical of highly malignant gliomas.
Tumor neural stem cell–generated i.c. tumors were
characterized by a peculiar morphology (E; 4
objective), and nest-like formations, reminiscent of
mitotically active anomalous glial cells, could be
identified in the core of the lesion (inset in E), as
opposed to U87-derived tumors (F), which con-
sisted of highly packed undifferentiated small
rounded single mitotic elements (inset in F).
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immunoreactive for the astroglial-specific marker GFAP (Fig. 4G--I)
and vimentin (not shown) and negative for neuronal (Tuj1) and
oligodendroglial antigens (GalC), just like typical human glioblasto-
mas multiforme (not shown). Similar to grafted U87 cells, medullo-
blastoma implants did not display immunoreactivity for astroglial
(Fig. 4F), neuronal, or oligodendroglial antigens (not shown).
Serial Transplantation of Tumor Neural Stem Cells. To con-
clusively demonstrate the stemness of glioblastoma multiforme–
Fig. 4. Tumor neural stem cells xenografted i.c. generate tumors, which reproduce the intraparenchymal invasion pattern, typical of human glioblastoma multiformes. Six weeks
after orthotopic implantation, tumor neural stem cell–derived tumors (A; human-specific antimitochondria staining in green) were characterized by an expanding area of growth, located
in the center of the tumor mass and by a surrounding “penumbra,” from which highly migratory cells departed, infiltrating the adjacent parenchyma and white matter (A, arrow; 4
objective). At the same time point, medulloblastoma–derived grafts (B; human-specific antinuclei staining in green; 10 objective) exhibited very poor capacity for migration,
spreading, and invasion, if any. Notably, U87-derived tumors (C; human-specific antimitochondria staining in green; 4 objective) were quite large in size, but cells did not exhibit
any migratory capacity, so that these tumors consisted of a progressively enlarging, well-defined cell mass, which remained confined to the site of injection. An elevated mitotic index
was exhibited by i.c. tumor neural stem cell tumors (D; Ki67 in red and human nuclei in green; 40 objective; arrows point to examples of double-labeled cells), whereas very few
cells within the medulloblastoma-derived grafts were indeed proliferating (E; Ki67 in red and human nuclei in green; 40 objective; arrow pointing to a double-labeled cell). In
medulloblastoma grafts, we could never find cells that expressed astroglial markers [F; GFAP in red and human mitochondria in green; 20 objective; note that GFAP
immunoreactivity (red) is confined outside the graft mass (green)]. Conversely, some cells in glioblastoma multiforme–derived tumor neural stem cell–generated tumors were found
to label with the anti-GFAP antibody (G, human mitochondria in green; H, anti-GFAP in red; merged confocal image in I; 20 objective).
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derived tumor neural stem cells, we performed sequential transplan-
tation experiments. This was done in analogy with the classical
hemopoietic serial repopulation paradigm used to identify true hemo-
poietic stem cells (38). Cultured tumor neural stem cells (primary
tumor neural stem cells) were transplanted into the mouse CNS to
establish a tumor from which secondary tumor neural stem cells were
recultured and then transplanted into new recipients. The successful,
sequential generation of brain tumors provided evidence that we had
isolated bona fide tumor neural stem cells.
Tumor neural stem cells, isolated from post-surgery specimens,
were expanded, cloned, and injected orthotopically, giving rise to
brain tumors. At the first sign of neurologic impairment (8–10 weeks
after transplantation), as produced by the expanding tumor mass (Fig.
5A and E), animals were sacrificed. The tumor was explanted by
careful dissection, which excluded the periventricular region of the
forebrain, highly enriched for stem cells and progenitors (ref. 9; Fig.
5B–D), and the cells were cultured under the same conditions used to
establish the original tumor neural stem cell cultures. Clonal neuro-
spheres were readily detected in these secondary cultures, which
exclusively contained cells that labeled positive with human-specific
markers and that were named post-transplantation–tumor neural stem
cells (Fig. 5F). Generation of primary spheres from tumor neural stem
cell–induced tumors occurred much faster than parental, primary
spheres, established from the original patient’s specimen (3 days for
post-transplantation–tumor neural stem cells compared with 20–40
days for primary, parental tumor neural stem cell lines). Cell lines
established from the post-transplantation–tumor neural stem cells also
expanded at a faster rate than their parental tumor neural stem cells
Fig. 5. Tumor neural stem cells self-renew in vivo, upon serial transplantation. The tumor mass established from the transplanted human tumor neural stem cells was dissected out
at the first sign of neurologic impairment, taking particular care of not including the stem cell–enriched periventricular region (arrows in A–D). This procedure was facilitated by the
large size of the in-growing tumor mass, which produced a macroscopic enlargement of the injected cerebral hemisphere (E, arrows). The tumor cells were then dissociated and placed
in culture under conditions identical to those used to establish tumor neural stem cell lines from the original human specimen. This resulted in the establishment of secondary tumor
neural stem cell (PT-TNSCs) lines, which contained exclusively cells of human origin, with no sign of rodent cell contamination (F; human-specific mitochondria staining in red and
nuclear 4,6-diamidino-2-phenylindole staining in blue; 20 objective). G, Post-transplantation–tumor neural stem cells were able to long-term expand in culture, even faster than the
original, parental tumor neural stem cell line. GBM, glioblastoma multiforme.
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(line glioblastoma multiforme 1022 as reference; Fig. 5G). This
suggests that the malignancy of serially transplanted post-transplan-
tation–tumor neural stem cells might have been exacerbated by the
exposure to the in vivo environment or that particularly aggressive
cells had been selected upon transplantation, tumor growth, and
reculturing.
When post-transplantation–tumor neural stem cell lines were dif-
ferentiated under the same conditions of their parental ones, all of the
three cell types could be detected. Thus, post-transplantation–tumor
neural stem cells retained multipotency after transplantation and re-
culturing (20  2.1% of Tuj1-IR cells; 52  5.4% of GFAP-IR cells;
24  0.7% of Tuj1/GFAP cells, n  10, two different secondary
glioblastoma multiforme 1022 cell lines analyzed). Furthermore, post-
transplantation–tumor neural stem cells maintained the same karyo-
typic features (not shown) and molecular signature of their parental
lines (see Fig. 6D, line 1022 and 1022PT), and when retransplanted
orthotopically, they were still capable of giving rise to new glioblas-
toma multiforme–like tumors, with characteristics identical to those
generated by primary tumor neural stem cells (not shown). In con-
clusion, tumor neural stem cells satisfy all of the critical criteria to be
defined as multipotent tumor neural stem cell lines, both in vitro and
in vivo (20).
Tumor Neural Stem Cells Display Tumor-Specific Properties.
In addition to the exacerbated growth rate displayed by most of the
glioblastoma multiforme–derived lines when compared with normal
human fetal neural stem cells (Fig. 1C), tumor neural stem cells were
also expected to bear tumor-specific features, such as highly unbal-
anced karyotypes and telomerase reactivation.
Karyotypic analysis was performed on all of the six lines, on U87
cells and on human fetal neural stem cells (Fig. 6A). Many different
numerical and structural chromosomal aberrations could be detected
in tumor neural stem cells and in U87 but not in human fetal neural
stem cells, which revealed a normal complement of chromosomes and
no genetic abnormalities. Intriguingly, aneuploidy of specific auto-
somes and sex chromosomes (monosomy 1, trisomy 7 and 22, and
disomy X) was retrieved most frequently in the three tumor neural
stem cell lines with the highest expansion potential (cluster A),
suggesting that peculiar aberrations may confer a certain degree of
Fig. 6. Karyotypic imbalance, telomerase reactivation, and molecular fingerprint characterize all glioblastoma multiforme–derived tumor neural stem cells. A, summary of the
chromosomal aberrations found in all of the different tumor neural stem cell lines. HFNSC, human fetal neural stem cell. B, the enzymatic activity of the RNA catalytic subunit of
telomerase as assessed by telomeric repeat amplification protocol assay in the different cell lines, normal human neural stem cells, and U87 glioma cells; C, telomere length, as measured
by Southern blotting in glioblastoma multiforme cell lines, normal human neural stem cells, and U87 glioma cells. M, marker; LW, low-weight standard; HW, high-weight standard.
D, a preliminary gene expression profile on tumor neural stem cells and control cell lines by semiquantitative reverse transcription-PCR. Tumor neural stem cell lines are displayed
as clustered into fast-growing (cluster A) or slow-growing (cluster B) cell lines.
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proliferation advantage to tumor neural stem cells. Conversely, slow-
growing lines (cluster B) showed line-specific, chromosomal aberra-
tions. Notably, long-term culturing did not affect the karyotypic
signature of tumor neural stem cells, which remained constant even at
high passages in culture (not shown).
Malignant transformation entails the acquisition of an immortal
phenotype, which requires active telomere-maintenance mechanisms
(39). We tested whether the catalytic subunit of the human ribonu-
cleoprotein enzyme telomerase reverse transcriptase, which provides
tumor cells with unlimited proliferation capacity by telomere length-
ening, was at work in glioblastoma multiforme–derived cell lines. By
means of the telomeric repeat amplification protocol assay, high
human telomerase reverse transcriptase activity was retrieved in all of
the glioblastoma multiforme–derived cell lines and in the correspond-
ing original tumor specimens (not shown), whereas normal human
fetal neural stem cells were telomerase negative (Fig. 6B), as shown
previously (40). We also assessed telomere length and detected sig-
nificant differences among the various tumor neural stem cell lines,
with lines 0821 and 1030 displaying very short telomeres, even
shorter than human fetal neural stem cells (Fig. 6C). Our observations
suggest that tumor neural stem cells, isolated from glioblastoma
multiformes, although displaying typical stem cell features, possess
line-intrinsic, tumor-related functional properties.
Molecular Phenotyping of Tumor Neural Stem Cells. To assess
whether the heterogeneity detected at the cellular and biochemical
level in various tumor neural stem cells could also be retrieved at the
molecular level (Fig. 6D), the gene expression profiles of the six
different lines were analyzed by semiquantitative reverse transcrip-
tion-PCR. The candidate genes for reverse transcription-PCR were
selected and clustered taking into account their restricted pattern of
expression in (1) normal neural progenitors; (2) brain tumors; (3) CNS
development. Normal human fetal neural stem cells, the glioblastoma
cell line U87MG, and human fetal whole brain tissue were used as
specimens of reference for the above gene clusters 1, 2, and 3,
respectively.
As expected, based on their cellular phenotype, the genetic profiles
of the different tumor neural stem cells could readily be clustered
based on the expression of specific gene sets. The fast-growing cell
lines 0627, 0913, and 1022 were characterized by similar gene ex-
pression patterns, whereas each one of the slow-growing lines 0821,
1030, and 1205 displayed a unique molecular signature. Nonetheless,
fast-growing lines (0627, 0913, and 1022) also showed cell-line–
specific variations in their gene expression profile, confirming that
despite the evidence for overlapping cellular and molecular charac-
teristics, each tumor neural stem cell line was ultimately, inherently
unique and phenotypically different from all of the others.
Intriguingly, the widest body of heterogeneity in terms of gene
expression occurred at the level of developmentally regulated genes,
which displayed line-specific, modulation patterns. For instance, the
homeobox gene Emx2, a regulator of self-renewal in neural stem cells
(23), also implicated in cortical development (41, 42), and its repres-
sor HOXA10 (43) were transcriptionally regulated in a reciprocal
fashion, with lines 0627, 0913, and 1022 (cluster A) displaying high
levels of Emx2 transcript and no detectable HOXA10 mRNA and lines
0821, 1030, and 1205 (cluster B) showing the opposite trend. Simi-
larly, genes such as Patched and Pax6 demonstrated a scattered
distribution across the different tumor neural stem cell lines, although
not correlated to any clear functional clustering. Conversely, a higher
degree of homogeneity between lines was retrieved when analyzing
tumor-related genes such as PTEN, p21, p27, p53, and MDR1. In
perspective, the line-specific molecular signature and the identifica-
tion of genes that play a key role in a given type of tumor neural stem
cell may be exploited to develop custom-fit therapies, by taking into
account the unique genetic background of the specific tumor cells
found in the glioblastoma multiforme of a specific patient.
DISCUSSION
This work reports on the isolation and identification of tumor neural
stem cells from human adult glioblastoma multiforme, which possess
the capacity to establish, sustain, and expand these tumors, even under
the challenging settings posed by serial transplantation experiments.
These data identify tumor neural stem cells as one of the cell lineages
involved in establishing the malignant, aggressive profile of this lethal
brain tumor.
Glioblastoma multiforme represents one of the most frequent brain
cancers and either may develop from lower grade astrocytic tumors
(secondary or progressive glioblastoma multiforme) or may arise very
rapidly de novo (primary glioblastoma multiforme; ref. 44). In both
cases, neither chemotherapy nor radiotherapy has been effective in
managing these cancers (45). Glioblastomas multiforme display a
rather heterogeneous cellular composition, as indicated by the term
“multiforme,” with some of the tumor cells bearing significant mi-
gratory capacity. This results in invasive spread, in the formation of
multiple secondary foci, and in frequent, recurrent growth. Therefore,
the identification of the cell type(s) involved in some or all of these
phenomena is critical from both a scientific and therapeutic stand-
point.
To date, three studies have indicated the presence of undifferenti-
ated neural precursors within pediatric or adult human brain tumors.
The initial study by Ignatova et al. (15) described the isolation of
neurosphere-forming, bipotent (neuronal/astroglial) precursors from
glioblastomas multiforme and was subsequently extended by Singh et
al. (16), who also demonstrated that bipotent progenitors from CNS
tumors (mostly medulloblastomas) displayed short-term self-renewal
(three passages in culture). The latter work also proposed that oligo-
dendrocytes might have been generated from tumor cells, but the use
of a promiscuous marker such as platelet-derived growth factor re-
ceptor , which simultaneously labels both oligodendrocytes and
neurons in culture (46), precluded any conclusion in this direction.
Similar findings were later reported by Hemmati et al. (17), who
described the absence of oligodendrocytes and the lack of tumorigenic
ability after intracerebral transplantation of tumor-derived cells.
Collectively, these studies show that cells endowed with some of
the characteristics expected from stem cells can be found within brain
tumors, thus raising some intriguing issues. First and foremost, can
aberrant neural precursors be involved in the establishment, expan-
sion, and recurrence of CNS cancers (i.e., are they tumorigenic?) or,
rather, do they emerge as the byproduct of the uncontrolled prolifer-
ation of the actual tumorigenic cells, which are developmentally
deranged? Second, if these precursors are tumorigenic, do they pos-
sess all of the features to qualify as tumor neural stem cells (20)?
The data presented here provide answers to these questions. They
describe the isolation and identification of human glioblastoma mul-
tiforme cells, which possess all of the defining features of somatic
stem cells, including ex vivo multipotency (i.e., the potential to simul-
taneously generate cells displaying antigenic reactivity for neuronal,
astroglial, and oligodendroglial markers in culture; refs. 47–49) and
the ability to establish and expand glioblastoma multiforme–like
tumors. The latter contain exclusively cells expressing astroglial
markers, as in typical human glioblastomas multiforme. Notably,
these cells can perpetuate glioblastoma multiforme–like tumors even
under the critical settings imposed by serial transplantation, thus
satisfying the most rigorous criteria to be classified as tumor neural
stem cells (20).
These findings were highly reproducible when analyzing tumor
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neural stem cells established from different specimens, regardless of
significant functional, karyotypic, and molecular differences between
the various tumor neural stem cells. This may account for the presence
within different glioblastoma multiforme specimens of tumor neural
stem cells with common general stem cell properties that, however,
are also characterized by unique, specimen-related, specific functional
and molecular attributes.
Our data seem to suggest that tumor neural stem cells are found
mainly within glioblastomas multiforme, although such a conclusion
should be taken with caution. In fact, although our findings are
consistent with those from Hemmati et al. (17) and show that cells
from medulloblastomas expand poorly in vitro and do not establish
tumors upon intracerebral grafting, they should not be construed as
evidence that tumor neural stem cells are not present in medulloblas-
tomas. It is possible that medulloblastomas contain cells that elicit
their full stem cell potential under different settings than those used to
date. Thus, it is intriguing that Kondo et al. (50) have reported on the
presence of tumorigenic stem-like cells in a rodent glioma cell line
(C6) that require different growth factors than those used in previous
studies to expand in culture.
The knowledge that cells with stem cell characteristics may be
involved in glioblastoma multiforme tumorigenesis is of paramount
importance for our understanding of how these tumors form and
expand and may provide an indication as to the key cellular and
molecular mechanism to be investigated and tackled for diagnostic
and therapeutic purposes. Unfortunately, it remains unclear whether
tumor neural stem cells in glioblastomas multiforme derive from the
transformation of normal human neural stem cells or whether their
presence therein reflects the result of the transformation and de-
differentiation of a more mature brain cell, which brought about
otherwise silent/latent stem cell properties (5). Nonetheless, the dem-
onstration of the existence within glioblastomas multiforme of tumor
neural stem cells with the capacity of establishing this type of tumor,
together with previous reports showing the existence within similar
cancers of bipotent, stem-like cells (15–17), lends to the hypothesis
that a hierarchical model of cell genesis may be at work within
malignant brain cancers.
To date, only a few glioblastoma multiforme cell lines have been
established (51–53) and used for studies on basic glioma biology or to
perfect therapy for glioblastoma multiforme (54–57). The tumor
neural stem cells described here can be used to routinely establish
adult human glioblastoma multiforme cell lines in a quick and repro-
ducible fashion. Of note, these cells reproduce the overall behavior of
glioblastomas multiforme closer than any other previously available
cell line. For example, when transplanted into immunosuppressed
mice, the most widely used human glioblastoma multiforme cell line,
the U87MG, gave rise to tumors that did not mimic the typical
glioblastoma multiforme characteristics. Conversely, upon orthotopic
transplant, all of the glioblastoma multiforme–derived, tumor neural
stem cell lines formed tumors bearing all of the primary traits of
human glioblastomas multiforme. Most importantly, cells in tumor
neural stem cell–founded tumors displayed, in vivo, the typical mi-
gratory capacity expected from glioblastoma multiforme malignant
cells, which was not observed when using U87, and, most impor-
tantly, retained their distinctive, line-specific proliferation and differ-
entiation attributes. Thus, the identification of tumor neural stem cells
also makes available cell lines of glioblastoma multiforme–initiating
cells, which may retain specimen-specific and, thus, patient-specific
traits. This may open new avenues to identify novel tumor cell
markers for therapeutic and diagnostic purposes and to develop pa-
tient-tailored pharmacologic approaches for the cure of glioblastomas
multiforme, aiming to target what may very well be the most aggres-
sive cell type found in glioblastomas multiforme, to date, which is the
tumor neural stem cell.
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